Enhanced reduction of multinodular goiter (MNG) can be achieved by stimulation with recombinant human thyrotropin (rhTSH) before radioiodine ((131)I) therapy. The objective was to compare the long-term efficacy and safety of two low doses of modified release rhTSH (MRrhTSH) in combination with (131)I therapy.
Fast, S., Hegedüs, L., Pacini, F., Pinchera, A., Leung, A.M., Vaisman, M., et al. (2014). Long-term efficacy of modified-release recombinant human thyrotropin augmented radioiodine therapy for benign multinodular goiter: results from a multicenter, international, randomized, placebo-controlled, dose-selection study. THYROID, 24(4), 727-35-735 [10.1089/thy.2013.0370].
Long-term efficacy of modified-release recombinant human thyrotropin augmented radioiodine therapy for benign multinodular goiter: results from a multicenter, international, randomized, placebo-controlled, dose-selection study
PACINI, FURIO;Castagna, Maria G;
2014-01-01
Abstract
Enhanced reduction of multinodular goiter (MNG) can be achieved by stimulation with recombinant human thyrotropin (rhTSH) before radioiodine ((131)I) therapy. The objective was to compare the long-term efficacy and safety of two low doses of modified release rhTSH (MRrhTSH) in combination with (131)I therapy.
| File | Dimensione | Formato | |
|---|---|---|---|
|
Fast Thyroid.pdf
non disponibili
Licenza:
NON PUBBLICO - Accesso privato/ristretto
Dimensione
277.09 kB
Formato
Adobe PDF
|
277.09 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
https://hdl.handle.net/11365/973277